


## Why Mitochondrial Therapy?

**Mitochondria are the battery of the cell** supplying cellular energy (ATP) to enable all the functionalities of life, such as proteins synthesis, DNA repair, waste removal, muscle contraction, etc.

**All degenerative diseases and aging start with damage to mitochondria** once energy production is depleted, the cell starts to degenerate.



**Mitochondrial therapy is the most transformative and impactful field for human health and longevity.**

## Leadership, Business & Funding

- **Experienced leadership** – proven track record of product development from inception to exit
- Extensive **funding experience** – millions USD raised
- Extensive experience in complex deals: **M&A, IPO, licensing**
- **Strategic IP construction** and management of large portfolios
- **1.5 Million USD invested by founders**
- All equity is held by the founders
- **Strategic business development plan** to ensure fast revenue and growth

## Cellergy is Closing the Gap to making mitochondria a viable commercial product

### Proprietary Source and Process

Non-transformed source, high-quality, scalable, cost-effective

### Manufacturing

massive quantities, down stream purification process in place, formulation for both local and systemic repeated administration  
Next – the world's first GMP production facility

### Allogeneic

AI based software for donor/recipient matching output

**We are unlocking an entire field of aging/longevity related therapies**

## Value Drivers

- Controlling manufacturing
- Extensive IP development
- Early licensing income
- Multiple out-licenses across industries
- Pre-clinical and clinical validation by partners

## Dev/Business Milestones

Early licensing income and validation by licensees

Building manufacturing capabilities while developing selected indications

6

months

Pre-clinical validation in selected animal models

12

months

First out-license deal

Mid-scale Non-GMP mitochondria ready for pre-clinical collaborations

18

months

Multiple out-license deals

First IND in first clinical indication

24

months

First IND by licensee

GMP certified, large scale mitochondria produced, and quality assured

30

months

Multiple INDs by licensees

IPO/M&A ready

60

months

Launch of approved pharma product by licensee